The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Private Equity - II | Alive

Total Raised




Last Raised

$100M | 9 yrs ago

About Emcure Pharmaceuticals

Emcure Pharmaceuticals is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. The company's core strength lies in developing and manufacturing differentiated pharmaceutical products in-house, which it commercializes through it's marketing infrastructure across geographies and relationships with multi-national pharmaceutical companies.

Emcure Pharmaceuticals Headquarter Location

Emcure House T 184, M.I.D.C., Bhosari

Pune, 411 026,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Emcure Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Emcure Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Emcure Pharmaceuticals Patents

Emcure Pharmaceuticals has filed 30 patents.

The 3 most popular patent topics include:

  • Antineoplastic drugs
  • Alkylating antineoplastic agents
  • Organochlorides
patents chart

Application Date

Grant Date


Related Topics




Cardiac arrhythmia, Ketones, Amines, TAAR1 agonists, Phenols


Application Date


Grant Date



Related Topics

Cardiac arrhythmia, Ketones, Amines, TAAR1 agonists, Phenols



Latest Emcure Pharmaceuticals News

IPO: Bain Capital-Backed Emcure Pharmaceuticals Looks To List

Aug 19, 2021

Family members of the promoters who own 33.55% stake BC Investments IV Ltd, an affiliate of Bain Capital, which owns 13.09% Other investors who own 4.23% In the offer for sale, the promoters are looking to sell up to 22.8 lakh equity shares, the promoter group is looking to sell up to 37.35 lakh shares, BC Investments is looking to sell up to 99.5 lakh shares and other shareholders will look to sell 22 lakh shares. The selling shareholders may also undertake a pre-IPO placement worth Rs 200 crore before filing the red herring prospectus, the DRHP said. Merchant bankers to the IPO include BoB Capital, Axis Capital, BofA Securities, Credit Suisse and JM Financial. Emcure develops, manufactures and markets a broad range of pharmaceutical products - formulations, biologics, APIs - across major therapeutic areas including gynaecology, cardiology, blood-related, oncology, respiratory, CNS and HIV. The company has more than 350 brands, 5 R&D centers and 14 manufacturing facilities across India, as per information on its website. It sells in over 70 countries. It is currently developing a Covid-19 vaccine on the mRNA platform, a company statement said. At least Rs 947.6 crore from the proceeds of the offer will be used to repay either full or a part of Emcure Pharma's borrowings, according to the DRHP. As of March 31, the company's total outstanding borrowings were at Rs 1,712 crore. Emcure Pharma's lenders include Export Import Bank of India, Aditya Birla Finance, Tata Capital, Shinhan Bank, Bajaj Finance, Bank of Maharashtra and Bank of Baroda. As of March 31, the company reported a consolidated net profit of Rs 419 crore, up over four times from Rs 101 crore reported a year ago. Consolidated total income for FY21 stood at Rs 6,092 crore, up 19% year-on-year. On June 4, the Mumbai bench of the National Company Law Tribunal approved the demerger of Emcure Pharma's U.S. market business under its arm Avet Lifesciences Ltd. BloombergQuint

Emcure Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Emcure Pharmaceuticals Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.